CD38 contributes to immune response, cell adhesion, and signal transduction. Furthermore, it plays a vital role in calcium signaling, acting as a second messenger to regulate muscle contraction, cell growth, fertilization, and cellular motility. Because of this role, CD38 is a target for tumor evasion and inflammatory-related diseases (BellBrook Labs, 2021).
PARG, along with PARP1 are the principal elements of the DNA damage response (DDR). A recent study showed that elevated levels of PARG reduced early tumorigenesis potential without decreasing cell viability. Because of this, PARG has become a target of interest for anticancer therapy (BellBrook Labs, 2022).
The Transcreener ADPR Assay allows researchers to screen compound libraries for CD38 or PARG modulators. This is an excellent tool to discover novel therapeutic treatments.